MedTrace Logo

Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)

NCT00600769 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2017-05-23

No results posted yet for this study

Summary

Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria

Conditions

  • Nontuberculous Mycobacteria
  • Mycobacterium Avium Complex

Interventions

DRUG

Clarithromycin

Dosage dependent on clinical factors such as age, weight and patient-specific health status

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • The University of Texas Health Science Center at Tyler

    lead OTHER

Principal Investigators

  • Richard J Wallace, MD · UTHSCT

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-01-31
Primary Completion
2006-11-30
Completion
2017-05-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600769 on ClinicalTrials.gov